Gabexin Mesilate is best described as which of the following in acute pancreatitis?

Study for the Medical Council of Canada Qualifying Examination (MCCQE) I. Engage with flashcards and multiple-choice questions with detailed feedback. Prepare confidently!

Multiple Choice

Gabexin Mesilate is best described as which of the following in acute pancreatitis?

In acute pancreatitis, enzymes released within the pancreas contribute to tissue injury and inflammation. Gabexate mesilate acts by inhibiting serine proteases, such as trypsin, which are central drivers of autodigestion. By blocking these enzymes, it aims to lessen inflammatory cascades and tissue damage, potentially reducing complications from the pancreatitis. This is why it’s described as a serine protease inhibitor used in acute pancreatitis. The evidence suggests it can lower some complication rates, but it does not reliably change overall mortality, so the benefit is limited and it isn’t a standard mortality-reducing therapy. It is not a proton pump inhibitor, an antiviral, or a beta-blocker, which explains why those options don’t fit.

In acute pancreatitis, enzymes released within the pancreas contribute to tissue injury and inflammation. Gabexate mesilate acts by inhibiting serine proteases, such as trypsin, which are central drivers of autodigestion. By blocking these enzymes, it aims to lessen inflammatory cascades and tissue damage, potentially reducing complications from the pancreatitis.

This is why it’s described as a serine protease inhibitor used in acute pancreatitis. The evidence suggests it can lower some complication rates, but it does not reliably change overall mortality, so the benefit is limited and it isn’t a standard mortality-reducing therapy. It is not a proton pump inhibitor, an antiviral, or a beta-blocker, which explains why those options don’t fit.

More practice questions